"Analysis of the development trend of China's pharmaceutical innovation and investment" forum was successfully held

Source: on the morning of November 16, 2016, the first session of "China Pharmaceutical Innovation and investment conference" was held successfully Five speakers from the fields of pharmaceutical innovation research and development, pharmaceutical big data and investment and financing analysis made wonderful special reports around innovative investment decisions; seven entrepreneurs and securities analysts in the field of pharmaceutical innovation and investment conducted interactive exchanges on the timing of investment in pharmaceutical innovation, with a warm atmosphere Li Jing, chairman of Yaodu Jingwei Information Technology Co., Ltd., in the special forum, introduced in detail that Yaodu, according to the law of drug research and development, mined and sorted out 40 selected small molecule chemical drug research and development projects by analyzing the comprehensive data of 6000 listed drugs in the world The key points provide reasonable suggestions based on big data for scientific project initiation of drug research and development, correct judgment of investable projects by investors, and improvement of chemical research and development efficiency Li Jing, chairman of Yaodu Jingwei Information Technology Co., Ltd., made a report Ding Dan, chief analyst of Guotai Junan pharmaceutical industry, shared the report on the opportunity analysis under the industry reform According to the report, China's pharmaceutical industry still has a huge growth space, which is far greater than other industries, and is the industry that investors focus on; the reform of the medical insurance system and the supply side reform optimize the pharmaceutical innovation environment; pharmaceutical enterprises need to change from single product, marketing winning, to cooperative R & D, merger and acquisition R & D, so as to promote development through innovation Ding Dan, chief analyst of Guotai Junan pharmaceutical industry, makes a report Professor Zhu Xun, President of tongshuyi new medicine talent club, analyzed the investment and financing opportunities and key points of innovative drugs He pointed out that at present, the investment options and valuation of Chinese medicine are unreasonable, and the investment efficiency is low The investment projects should be based on the scientific understanding of basic research and development and clinical data We should be cautious in the hot innovation field of global investment and the innovation with future development potential The new field should have keen insight Prof Zhu Xun, director of new medicine talent Club Zhang Dawei, member of the Executive Committee and chief risk officer of China Securities inter agency Quotation System Co., Ltd., introduced that the inter agency quotation system of China Securities is a network platform providing specialized investment and financing services for participants with the core functions of private product issuance and transfer, interconnection, registration and settlement, information services, etc.; in the future, China Securities Association and China pharmaceutical innovation promotion association will work together To guide the establishment of China pharmaceutical innovative financial comprehensive service platform based on the company's platform, and to provide innovative enterprises with third-party independent quotation, professional valuation, diversified financing, innovation cultivation, industry policy guidance and consultation, international cooperation and other professional services Zhang Dawei, member of the Executive Committee and chief risk officer of China Securities inter agency Quotation System Co., Ltd made a report Dr Xie Yuli, director of Product Development Service Department of Wuxi apptec, interpreted how to set up a project for pharmaceutical innovation research: to imitate innovation, it is necessary to form differentiated project establishment thinking in the aspects of target selection, clinical value, clinical scheme design, etc., collect research and development information of early research projects in the world through multiple channels, and comb and analyze basic data from multiple perspectives to find differentiated research and development inspiration Dr Xie Yuli, director of product development and Service Department of Wuxi Pharmaceutical Co., Ltd., made a report Xu Jiaxi, chief analyst of Societe Generale Securities, acted as the host of the interactive discussion of the guests, and worked with Wang Peng, vice president of Yabao Pharmaceutical Group Co., Ltd., Zhuo Yongqing, senior Consultant of rdpac, researcher of the Institute of health law, Tsinghua University School of law, and chairman and CEO of Yasheng pharmaceutical Yang Dajun, executive president of Suzhou Kangning Jierui Biotechnology Co., Ltd Xu Ting, vice president of CITIC Industrial Fund Investment Li Jingjing, founder and chairman of Yuance Investment Co., Ltd Zhang Yichi jointly discussed the impact of investment and policy environment on pharmaceutical innovation enterprises, and how investment institutions evaluate pharmaceutical innovation enterprises and projects The guests believed that the investment valuation should be based on the clinical efficacy and value potential of the product, while the pharmaceutical innovation also needs good policy environment support; the same innovative product will have different capital involvement in different R & D stages, and different investment institutions will jointly promote the pharmaceutical innovation R & D through cooperation and exchange of high-quality investment targets and data analysis and other resources Guests expressed optimistic expectations for innovation investment in the pharmaceutical industry "Analysis on the development trend of China's pharmaceutical innovation and investment" was held during the interactive discussion of guests The special forum, which enables the pharmaceutical industry innovation entrepreneurs and investors to directly discuss the connection between pharmaceutical innovation and investment face to face, is conducive to promoting the collision and connection between the pharmaceutical industry and the investment community on the concept and standard of pharmaceutical project selection, reducing the huge difference between the two sides in the valuation of the target, and better promoting the earlier and deeper involvement of social capital in pharmaceutical innovation The design of Forum Report and interactive theme is novel, which attracts great attention of the participants After the wonderful report, the audience actively asked questions in the interactive link, which directly hit the core issues of R & D and investment, keeping the atmosphere of the venue warm all the time, achieving the expected purpose of promoting effective communication between the pharmaceutical R & D and investment circles, and achieving good results